BREAKING NEWS

BeyondSpring announces submission of New Drug Application (NDA) to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN).
Read more

12.01.2010

Clinical Cancer Research (2010) 16:5892-5899

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas